This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

EARLY SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
7-9 March 2023
Westin Miyako KyotoKyoto, Japan

Tadashi Umemoto, PhD
General Manager, Research and Development at Luxna Biotech Co., Ltd.

Profile

Tadashi Umemoto is a General Manager of R&D at Luxna Biotech since 2018. Umemoto is managing R&D to develop the Luxna’s XNA incorporated Antisense Platform, or LuxiAP. Before joining Luxna Biotech, Umemoto has drug discovery experience in Takeda pharmaceuticals about nucleic acid therapeutics and peptide medicine. Umemoto received his Ph.D in nucleic acid chemistry from the University of Tokyo (supervised by prof. Wada) and his postdoctoral training at University of Southern Denmark (supervised by J. Wengel).

Agenda Sessions

  • Recent Progress of Luxna’s Chemistry Platform for Antisense Oligonucleotide Therapeutics

    12:00pm